Quality & complianceOfficial

FDA warns Malaysian seller over unapproved embryonic stem cell and placenta products

🇺🇸 FDA CBER · Tue 27 Oct 2026

CBER says Beaute Bounty's website markets embryonic stem cell and placenta-derived products with disease claims, without the approved biologics licence the agency requires.

The US Food and Drug Administration's Center for Biologics Evaluation and Research has issued a warning letter, dated 25 September 2026 (reference CBER 26-729163), to Beaute Bounty of Kuala Lumpur, Malaysia. The agency says the firm sells unapproved new drugs and unlicensed biological products through its website.

FDA reviewed the company's online stem cell and placenta collection and named three products: Evgenis Totipotent Embryonic Stem Cells, Laennec and Melsmon Placenta Japan, all offered for allogeneic use. The agency cites claims on the site that it says show disease-treatment intent. These include statements about neurodegenerative conditions, cardiovascular disease and diabetes for the stem cell product. The placenta hydrolysate products carry claims on liver hardening, anaemia, and skin and cell regeneration.

On that basis, CBER concludes the products are drugs and biological products. It also classes them as human cells, tissues, or cellular or tissue-based products (HCT/Ps). The agency says they do not meet the homologous-use criterion in 21 CFR 1271.10(a), because they are promoted for purposes other than the basic function of embryonic stem cells or placenta in the donor. They therefore cannot rely on the lighter regulation under section 361 of the Public Health Service Act. FDA adds that none of the exceptions in 21 CFR 1271.15 apply and that no biologics licence application is approved for the products.

The letter says it is not an exhaustive list of deficiencies and asks the company to check its website for other violating products and to prevent recurrence. It warns that failure to respond adequately may bring regulatory action without further notice. The source text is cut off before the list of possible actions is complete.

What it means for your team

  • FDA's reach extends to overseas online sellers whose products can be introduced into US interstate commerce; the letter targets website claims rather than a specific shipment.
  • Disease and function claims on a website can establish intended use, which moves an HCT/P out of the section 361 pathway and into drug and biologics requirements.
  • Homologous use is assessed against the product's basic function in the donor, so claims on neurodegenerative, cardiovascular or metabolic disease fall outside it.
  • Compliance and market-access teams handling cell- or tissue-derived products should review marketing language and confirm the correct regulatory pathway before sale.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.

More Quality & compliance All →